EyePoint Inc. (NASDAQ:EYPT) on Monday released topline results from its pivotal Phase 3 LUGANO clinical trial evaluating DURAVYU for the treatment of wet age-related macular degeneration.

While key secondary endpoints showed significant clinical progress, the study failed to meet its primary visual acuity endpoint due to a confounding patient subgroup.

“We are pleased to see that DURAVYU provided clinically meaningful results in the LUGANO trial. The outstanding outcomes across key secondary endpoints, paired with visual improvement, reinforce our confidence in DURAVYU’s potential to transform the current wet AMD treatment paradigm,” said Jay S. Duker, M.D., President and CEO of EyePoint. “While the primary endpoint result for the full dataset was unexpected, the consistently positive results from the pre-specified secondary endpoints and the ad hoc analysis on the primary endpoint present a compelling case for DURAVYU as a new potential therapeutic option for wet AMD. We look forward to a potential New Drug Application (NDA) filing with FDA in the first half of 2027, pending LUCIA results in the fourth quarter of 2026.”

EyePoint shares gained 9% to trade at $5.31 on Tuesday.

These analysts made changes to their price targets on EyePoint following the announcement.

  • Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and lowered the price target from $35 to $17.
  • RBC Capital analyst Lisa Walter downgraded the stock from Outperform to Sector Perform and cut the price target from $37 to $5.
  • Chardan Capital analyst Andreas Argyrides downgraded the stock from Buy to Neutral and slashed the price target from $65 to $5.
  • HC Wainwright & Co. analyst Yi Chen downgraded the stock from Buy to Neutral.

Considering buying EYPT stock? Here’s what analysts think:

Photo via Shutterstock